Generate Investment Management Ltd Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Generate Investment Management Ltd increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 56.5% in the 3rd quarter, Holdings Channel.com reports. The firm owned 18,778 shares of the biopharmaceutical company’s stock after buying an additional 6,778 shares during the quarter. Generate Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $10,558,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 686 shares during the period. CreativeOne Wealth LLC grew its position in shares of Regeneron Pharmaceuticals by 16.6% during the 1st quarter. CreativeOne Wealth LLC now owns 520 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 74 shares in the last quarter. Focus Partners Advisor Solutions LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $538,000. Adage Capital Partners GP L.L.C. boosted its stake in Regeneron Pharmaceuticals by 109.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 92,745 shares of the biopharmaceutical company’s stock valued at $58,822,000 after buying an additional 48,396 shares during the period. Finally, Amundi grew its position in Regeneron Pharmaceuticals by 3.4% during the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company’s stock worth $979,794,000 after buying an additional 52,166 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research analyst reports. Canaccord Genuity Group lifted their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Royal Bank Of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday. BMO Capital Markets increased their target price on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Finally, Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, December 20th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $779.45.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $773.94 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $792.77. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock has a market cap of $81.34 billion, a PE ratio of 18.53, a price-to-earnings-growth ratio of 2.24 and a beta of 0.37. The business has a fifty day simple moving average of $711.47 and a 200-day simple moving average of $614.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the prior year, the business earned $12.46 EPS. The business’s revenue for the quarter was up .9% on a year-over-year basis. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.